Evaluation of PF-08046050 (SGN-CEACAM5C) in Adults with Advanced Non-Small Cell Lung Cancer, Colorectal Cancer, and Other Solid Tumors

The primary objective of this study is to evaluate the efficacy and safety of **PF-08046050 (SGN-CEACAM5C)** in adults with advanced solid tumors. The study focuses on several types of cancer, including **non-small cell lung cancer** (both nonsquamous and squamous), **colorectal cancer**, **gastroesophageal junction adenocarcinoma**, **small cell lung cancer**, **gastric cancer**, and **pancreatic carcinoma**. Understanding the therapeutic potential of PF-08046050 in these malignancies is clinically relevant as it may offer new treatment options for patients with limited alternatives. The study does not specify any secondary objectives.

The clinical trial involves a total of **270 participants** diagnosed with various types of cancer, including **non-small cell lung cancer** (both squamous and nonsquamous), colorectal cancer, gastroesophageal junction adenocarcinoma, small cell lung cancer, gastric cancer, and pancreatic carcinoma. The study population comprises both male and female subjects, with an age range corresponding to categories 3 and 4, indicating adult participants. The trial includes a vulnerable population, although specific details regarding the nature of this vulnerability are not provided. Participants were selected based on unspecified criteria, and no specific lifestyle considerations such as diet or physical activity are mentioned. The sponsor has not disclosed detailed inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the investigational product PF-08046050 (SGN-CEACAM5C) in adults with advanced **solid tumors**. The study will focus on several types of cancer, including **non-small cell lung cancer** (both squamous and nonsquamous), **colorectal cancer**, **gastroesophageal junction adenocarcinoma**, **small cell lung cancer**, **gastric cancer**, and **pancreatic carcinoma**. This trial is structured as a Phase 1 study, which typically involves a small group of participants to assess the safety, tolerability, and pharmacokinetics of the investigational product. The trial is expected to commence recruitment on June 30, 2024, and is projected to conclude by March 31, 2030.

The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to receive either the investigational product or a control, with neither the participants nor the investigators aware of the group assignments. This approach minimizes bias and allows for a more objective assessment of the investigational product's effects.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will enter the treatment phase, during which they will attend regular follow-up visits to monitor their response to the treatment and any potential adverse effects. These visits will include comprehensive assessments such as physical examinations, laboratory tests, and imaging studies as necessary. The end-of-study visit will mark the conclusion of the participant's involvement, during which final evaluations will be conducted to gather data on the long-term effects of the treatment.

The expected duration of participant involvement will vary depending on individual response and the progression of the disease. However, participants may be withdrawn from the study early if they experience unacceptable toxicity, disease progression, or if they choose to withdraw consent. The study protocol will outline specific criteria for early termination to ensure participant safety and the integrity of the trial data.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and preliminary efficacy. The trial is scheduled to commence recruitment on June 30, 2024, with an estimated completion date of March 31, 2030. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 1 trials often involve the collection of data related to pharmacokinetics and pharmacodynamics, as well as initial observations of therapeutic effects. The methods for measuring and analyzing efficacy will likely include validated scales and laboratory tests, consistent with standard practices in early-phase clinical research. The trial will adhere to rigorous protocols to ensure the accurate collection and analysis of efficacy data, contributing to the overall assessment of the investigational product's potential benefits.